|
Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype Clinical research trials and Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype. Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype clinical trial. Subjects typically recieve the finest healthcare available for their Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "V" Clinical Trials Conditions > Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype  Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype
Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype
For Condition: B Cell Lymphoma,Follicular Lymphoma,Neoplasm
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: Patients undergo chemotherapy until remission is obtained, or disease has been stable for two cycles of chemotherapy, or progressive disease develops. Three to six months after completion of chemotherapy, patients who have achieved complete clinical remission or minimal disease status receive a series of 5 injections (given 1-2 months apart) of a vaccine consisting of 0.5 mg autologous tumor-derived immunoglobulin (Id) conjugated to KLH. The vaccine is administered with subcutaneous QS-21 as an immunological adjuvant.
Details: The idiotype of the immunoglobulin on a given B cell malignancy (Id) can serve as a clonal marker, and a previous pilot study in lymphoma patients has demonstrated that autologous Id protein can be formulated into an immunogenic, tumor specific antigen by conjugation to a carrier protein (KLH) and administration with an emulsion-based adjuvant. The objectives of this study are: 1) to evaluate feasibility and toxicity of new vaccine formulations, and 2) to evaluate cellular and humoral immune responses against the unique idiotype of the patient's lymphoma. The goal of this study is to treat patients with follicular lymphomas to complete remission or minimal residual disease with chemotherapy. Six to twelve months after completion of chemotherapy, in an effort to reduce the relapse rate (by eradicating microscopic disease resistant to chemotherapy), patients will receive one of two new formulations of an autologous Id vaccine.
Eligibility:
Study Type: Interventional, Treatment, Safety
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Sex: Male and female. Age: Patients must be greater than or equal to 18 years old. Patients must meet all of the following eligibility criteria: Tissue diagnosis of: follicular small cleaved cell or follicular mixed lymphoma with surface IgM, IgA, or IgG phenotype with a monoclonal heavy and light chain. Stage III or IV lymphoma. A single peripheral lymph node of at least 2x2 to 3x3 cm size and accessible for biopsy/harvest. Karnofsky status greater than or equal to 70%. Life expectancy of greater than 1 year. Serum creatinine less than or equal to 1.5 mg/dl unless felt to be secondary to lymphoma. Bilirubin less than or equal to 1.5 mg/dl unless felt to be secondary to lymphoma or Gilbert's disease. SGOT/SGPT less than or equal to 3.5 upper limit of normal. Ability to give informed consent. Ability to return to clinic for adequate follow-up for the period that the protocol requires. EXCLUSION CRITERIA: The presence of any exclusion criteria listed below will prohibit entry onto protocol: Prior total body irradiation. Presence of antibodies to HIV or hepatitis B surface agents or other active infectious process. Pregnant or lactating. Fertile men and women must plan to use an effective contraception. A beta-HCG level will be obtained in women of child-bearing potential. Patients with previous or concomitant malignancy, regardless of site, except curatively treated squamous or basal cell carcinoma of the skin, or effectively treated carcinoma in situ of the cervix. Patients unwilling to give informed consent. Any medical or psychiatric condition that in the opinion of the protocot chairman would compromise the patient's ability to tolerate treatment. Patients with CNS lymphoma (current or previously treated) will not be eligible.
Total Enrollment: 30
Location and Contact Information:
National Cancer Institute (NCI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 970077; 97-C-0077
Study Start Date: January 30, 1997
Record last reviewed: January 1, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001572
Other Follicular Lymphoma Studies:
1. Clinical Evaluation of a Laser Heated, Fiberoptic-Coupled Radiation Dose Verification System
2. Evaluation, Treatment, and Natural History of Children with Cancer
3. Continuing Care and Treatment for Patients with Cancer/AIDS/Skin Disease
4. Phase 1 Study of Imatinab (STI571) in Patients with Advanced Cancer and Liver Dysfunction
5. A Pilot Study of Oxaliplatin in Combination with Capecitabine in Adult Cancer Patients
Related Studies:
Other Follicular Lymphoma Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype
|
|
|
|
|
|
|
|
